

# Biosimilars 2017 Global Market Expected to Grow at CAGR of 55.52% and Forecast to 2021

*Wiseguyreports.Com Publish New Market Research Report On-“Biosimilars 2017 Global Market Expected to Grow at CAGR of 55.52% and Forecast to 2021”.*

PUNE, INDIA, October 6, 2017 / EINPresswire.com/ --

## [Biosimilars Market 2017](#)

Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator's product. They have many similarities, but are not identical to, the reference biopharmaceutical product.

The analysts forecast the global biosimilars market to grow at a CAGR of 55.52% during the period 2016-2020.

### Covered in this report

The report covers the present scenario and the growth prospects of the global biosimilars market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of products such as somatropin, erythropoietin, colony-stimulating factors (CSF), interferons, interleukins, insulin and insulin analogs, follicle stimulating hormones (FSH), monoclonal antibodies (mAbs), and low molecular weight heparins (LMWH).

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

Request a Sample Report @ <https://www.wiseguyreports.com/sample-request/592563-global-biosimilars-market-2016-2020>

The report, Global Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth



prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

#### Key vendors

- Biocon
- Celltrion
- Dr. Reddy's Laboratories
- Hospira
- Sandoz
- STADA
- Teva Pharmaceuticals

#### Other prominent vendors

- 3SBio
- Accord Healthcare
- AET Biotech
- Allergan
- Alvaris Pharma
- Amega Biotech
- Amgen
- Apotex
- Aspen
- AstraZeneca
- Aurobindo Pharma
- Baxter
- Bharat Serums
- Bio Sidus
- Biogen
- Bionovis
- Bioton
- BioXpress Therapeutics
- Boehringer Ingelheim
- Boston Oncology
- Cipla
- Coherus Biosciences
- Daiichi Sankyo
- Emcure Pharmaceuticals
- Gedeon Richter
- GeneScience Pharmaceuticals
- GSK

#### Key questions answered in this report

- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

## Table of Contents –Analysis of Key Points

### PART 01: Executive summary

- Highlights

### PART 02: Scope of the report

- Market overview
- Top-vendor offerings
- Assumptions

### PART 03: Market research methodology

- Research methodology
- Economic indicators

### PART 04: Introduction

### PART 05: Pipeline portfolio

### PART 06: Market landscape

- Market overview
- Five forces analysis

### PART 07: Market segmentation by application

- Global blood disorders biosimilars market
- Global oncology biosimilars market
- Global chronic and autoimmune diseases biosimilars market
- Global growth hormone deficiency biosimilars market
- Global infectious diseases biosimilars market

### PART 08: Market segmentation by end-user

- Hospitals
- Retail pharmacies

### PART 09: Geographical segmentation

### PART 10: Market drivers

- Rise in number of patent expiries
- Need for cost-effective treatment
- Reimbursement benefits for biosimilars
- Favorable government regulations
- Promising pipeline

### PART 11: Impact of drivers

### PART 12: Market challenges

- Physicians reluctance to prescribe biosimilars
- Multiple manufacturing complexities
- Risks related to drug failure
- Limited availability of biosimilar products
- Difficulties in patient recruitment for conducting clinical trials

### PART 13: Impact of drivers and challenges

### PART 14: Market trends

- Emergence of biosimilars

- Outsourcing of biosimilar manufacturing activities
  - Need for high investment in R&D
  - High growth in the emerging markets
  - Rising number of strategic collaborations
- .....Continued

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.